Acute-on-Chronic Liver Failure Market Set for Meaningful Growth by 2034: Advancing Research and Emerging Therapeutics | DelveInsight

Acute-on-Chronic Liver Failure (ACLF) is a life-threatening condition characterized by acute hepatic decompensation in patients with pre-existing chronic liver disease, often accompanied by multi-organ failure and a high short-term mortality rate. The condition remains a major clinical and therapeutic challenge due to its rapid onset, complex pathophysiology, and the lack of standardized treatment options. However, with improved understanding of immune dysfunction, systemic inflammation, and hepatic regeneration, the landscape for ACLF is beginning to shift.

DelveInsight's latest report, "Acute-on-Chronic Liver Failure (ACLF) - Market Insight, Epidemiology, and Market Forecast - 2034," provides an extensive analysis of the disease burden and evolving market dynamics. The report offers in-depth epidemiological insights across major markets-the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan-along with segmentation by severity, precipitating events, and underlying liver conditions such as cirrhosis or hepatitis B.

The ACLF market is currently dominated by supportive care, organ support, and liver transplantation. However, recent advances in stem cell therapy, immunomodulators, and bioartificial liver systems signal promising developments. With a growing pipeline of potential therapies targeting inflammation, cell regeneration, and organ preservation, the market is expected to witness steady growth over the next decade.

As clinical trials continue to evaluate novel approaches and biomarker-driven strategies, the ACLF treatment landscape is poised for transformation, offering renewed hope for improving outcomes in this high-risk patient population.

Request a sample and uncover the latest breakthroughs shaping the acute-on-chronic Liver Failure market landscape and future outlook @ https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Acute-On-Chronic Liver Failure Market Report:
• The Acute-on-chronic liver failure market is expected to grow significantly through the forecast period (2024-2034).
• In 2023, there were 61.5K diagnosed cases of Acute-on-chronic liver failure across the 7MM.
• The US accounted for 21% of ACLF cases, while EU4 and the UK contributed 73%, and Japan represented 6%.
• The CANONIC study reported ACLF prevalence in Europe as 49% Grade 1, 35% Grade 2, and 16% Grade 3 cases.
The 28-day transplant-free mortality rate for ACLF patients was 32.8%, significantly higher than 1.9% for non-ACLF patients.
• In the US, infection-associated ACLF with two or more organ failures made up around 24% of cases.
• In Italy, ACLF was identified in 12% of hospitalized cirrhotic patients, showing regional variability in disease burden.
• The ACLF market is projected to grow steadily from 2024 to 2034, supported by a rising prevalence of liver diseases and pipeline therapies.
• Investigational therapies like Albumin 5% (PE-A 5%) and VS-01 are expected to drive future market growth.
• Currently, there are no approved treatments for ACLF, highlighting a major unmet need in clinical management.
• In April 2025, eGenesis and OrganOx received FDA clearance for their IND application for EGEN-5784-a genetically engineered porcine liver, combined with the OrganOx ELC system, to support ACLF patients with decompensated liver function in intensive care.
• In February 2025, Genfit Biopharma reported that, in addition to the anticipated Phase II readout of the UNVEIL-IT study evaluating VS-01 in the second half of the year, the company expects to release up to three clinical datasets from its ACLF pipeline by the end of 2025.
• Emerging therapies for acute-on-chronic liver failure include ALBUTEINE (albumin 5%), VS-01, and others.
• Key companies involved in the treatment of acute-on-chronic liver failure include Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Martin Pharmaceuticals, Cipla, and others.

To know in detail about the acute-on-chronic liver failure market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute-On-Chronic Liver Failure Overview
Acute-on-chronic liver failure (ACLF) is a syndrome that develops in patients with chronic liver disease, with or without prior cirrhosis, marked by sudden liver decompensation leading to liver failure. This is typically indicated by jaundice and an elevated international normalized ratio (INR), along with failure of one or more extrahepatic organs. ACLF carries a high risk of mortality within 28 days to three months after onset.

Chronic liver disease can progress to cirrhosis, which has two phases: compensated (without symptoms) and decompensated (with complications such as jaundice, ascites, variceal bleeding, or hepatic encephalopathy). Various triggers-including viral infections, drug toxicity, alcohol abuse, ischemic injury, surgery, or sepsis-can exacerbate chronic liver disease and lead to liver and extrahepatic organ failure.

ACLF is categorized into three types based on the patient's liver status: Type A occurs in non-cirrhotic chronic liver disease, Type B in previously compensated cirrhosis, and Type C in previously decompensated cirrhosis. It represents an advanced stage of chronic liver disease marked by multi-organ failure.

Get a free sample for the acute-on-chronic liver failure market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute-On-Chronic Liver Failure Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Acute-On-Chronic Liver Failure Epidemiology Segmentation:
The acute-on-chronic liver failure market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Prevalent Cases of ACLF
• Total Diagnosed Prevalent Cases of ACLF
• Diagnosed Prevalent Cases of ACLF by Grade
• Gender-Specific Diagnosed Prevalent Cases of ACLF
• Total Treated Cases of ACLF

Acute-On-Chronic Liver Failure Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Acute-On-Chronic Liver Failure throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Acute-On-Chronic Liver Failure drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Acute-On-Chronic Liver Failure, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Acute-On-Chronic Liver Failure therapeutics.

Explore how emerging acute-on-chronic liver failure therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute-On-Chronic Liver Failure Market Outlook
Currently, there is no specific, effective treatment for ACLF, with management primarily focused on early diagnosis, addressing underlying triggers like bacterial infections, hepatitis B, and alcoholic hepatitis, and providing supportive care for organ failures. Prognosis evaluation and decisions regarding liver support, including liver transplantation (LT), are critical, though LT remains limited by donor availability and contraindications in many patients.

Therapies for ACLF aim to prevent progression of multiorgan dysfunction, such as renal failure, sepsis, metabolic imbalances, cerebral edema, encephalopathy, and coagulopathy. However, pharmacological treatments generate less revenue compared to surgical or procedural interventions, highlighting a significant market gap. Recognizing this, major pharmaceutical companies are actively pursuing innovative treatment options for sustained market growth. Given the complex nature of ACLF, single-agent therapies are unlikely to suffice, driving a shift towards multifaceted therapeutic strategies.

Research advancements and extensive global data over the past decade have accelerated development efforts. The upcoming introduction of novel therapies is expected to stimulate market expansion. Leading players like Grifols Therapeutics and GENFIT (Versantis AG) are developing promising candidates, including Albumin 5% (PE-A 5%) and VS-01, among others.

Acute-On-Chronic Liver Failure Market Drivers
• Rising prevalence of chronic liver diseases such as hepatitis and non-alcoholic fatty liver disease (NAFLD), increasing the patient pool at risk for ACLF.
• Advancements in therapeutic research and development, with promising novel treatments like Albumin 5% (PE-A 5%) and VS-01 entering clinical trials, fueling market growth.

Acute-On-Chronic Liver Failure Market Barriers
• Lack of approved, specific therapies for ACLF, resulting in limited treatment options and slow commercial uptake.
• The complexity of ACLF pathophysiology requires multifaceted treatment approaches, making drug development and clinical management challenging.

Scope of the Acute-On-Chronic Liver Failure Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Acute-On-Chronic Liver Failure Companies: Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Martin Pharmaceuticals, Cipla, and others.
• Key Acute-On-Chronic Liver Failure Therapies: ALBUTEINE (albumin 5%), VS-01, and others.
• Acute-On-Chronic Liver Failure Therapeutic Assessment: Acute-On-Chronic Liver Failure currently marketed, and Acute-On-Chronic Liver Failure emerging therapies.
• Acute-On-Chronic Liver Failure Market Dynamics: Acute-On-Chronic Liver Failure market drivers and Acute-On-Chronic Liver Failure market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Acute-On-Chronic Liver Failure Unmet Needs, KOL's views, Analyst's views, Acute-On-Chronic Liver Failure Market Access and Reimbursement.

To learn more about acute-on-chronic liver failure companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Acute-On-Chronic Liver Failure Market Report Introduction
2. Executive Summary for Acute-On-Chronic Liver Failure
3. SWOT analysis of Acute-On-Chronic Liver Failure
4. Acute-On-Chronic Liver Failure Patient Share (%) Overview at a Glance
5. Acute-On-Chronic Liver Failure Market Overview at a Glance
6. Acute-On-Chronic Liver Failure Disease Background and Overview
7. Acute-On-Chronic Liver Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute-On-Chronic Liver Failure
9. Acute-On-Chronic Liver Failure Current Treatment and Medical Practices
10. Acute-On-Chronic Liver Failure Unmet Needs
11. Acute-On-Chronic Liver Failure Emerging Therapies
12. Acute-On-Chronic Liver Failure Market Outlook
13. Country-Wise Acute-On-Chronic Liver Failure Market Analysis (2020-2034)
14. Acute-On-Chronic Liver Failure Market Access and Reimbursement of Therapies
15. Acute-On-Chronic Liver Failure Market Drivers
16. Acute-On-Chronic Liver Failure Market Barriers
17. Acute-On-Chronic Liver Failure Appendix
18. Acute-On-Chronic Liver Failure Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.